Sensus Healthcare, Inc.
Sensus Healthcare, Inc. SRTS Peers
See (SRTS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SRTS | $4.46 | -4.29% | 73.57M | 10.88 | $0.41 | N/A |
| ABT | $134.78 | +1.07% | 234.50B | 17.53 | $7.69 | +1.69% |
| BSX-PA | $122.18 | +2.37% | 175.45B | 230.53 | $0.53 | N/A |
| BSX | $106.04 | +1.12% | 156.87B | 77.40 | $1.37 | N/A |
| SYK | $394.29 | +0.53% | 150.68B | 53.21 | $7.41 | +0.83% |
| MDT | $86.42 | +0.36% | 110.84B | 26.35 | $3.28 | +3.25% |
| EW | $78.00 | +1.46% | 45.75B | 32.23 | $2.42 | N/A |
| DXCM | $85.48 | -0.22% | 33.52B | 64.27 | $1.33 | N/A |
| STE | $251.44 | +1.85% | 24.70B | 40.75 | $6.17 | +0.89% |
| PODD | $324.75 | +0.85% | 22.85B | 56.28 | $5.77 | N/A |
Stock Comparison
SRTS vs ABT Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, ABT has a market cap of 234.50B. Regarding current trading prices, SRTS is priced at $4.46, while ABT trades at $134.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas ABT's P/E ratio is 17.53. In terms of profitability, SRTS's ROE is +0.03%, compared to ABT's ROE of +0.24%. Regarding short-term risk, SRTS is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs BSX-PA Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, BSX-PA has a market cap of 175.45B. Regarding current trading prices, SRTS is priced at $4.46, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, SRTS's ROE is +0.03%, compared to BSX-PA's ROE of +0.10%. Regarding short-term risk, SRTS is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs BSX Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, BSX has a market cap of 156.87B. Regarding current trading prices, SRTS is priced at $4.46, while BSX trades at $106.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas BSX's P/E ratio is 77.40. In terms of profitability, SRTS's ROE is +0.03%, compared to BSX's ROE of +0.10%. Regarding short-term risk, SRTS is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs SYK Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, SYK has a market cap of 150.68B. Regarding current trading prices, SRTS is priced at $4.46, while SYK trades at $394.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas SYK's P/E ratio is 53.21. In terms of profitability, SRTS's ROE is +0.03%, compared to SYK's ROE of +0.11%. Regarding short-term risk, SRTS is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs MDT Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, MDT has a market cap of 110.84B. Regarding current trading prices, SRTS is priced at $4.46, while MDT trades at $86.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas MDT's P/E ratio is 26.35. In terms of profitability, SRTS's ROE is +0.03%, compared to MDT's ROE of +0.09%. Regarding short-term risk, SRTS is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs EW Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, EW has a market cap of 45.75B. Regarding current trading prices, SRTS is priced at $4.46, while EW trades at $78.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas EW's P/E ratio is 32.23. In terms of profitability, SRTS's ROE is +0.03%, compared to EW's ROE of +0.49%. Regarding short-term risk, SRTS is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs DXCM Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, DXCM has a market cap of 33.52B. Regarding current trading prices, SRTS is priced at $4.46, while DXCM trades at $85.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas DXCM's P/E ratio is 64.27. In terms of profitability, SRTS's ROE is +0.03%, compared to DXCM's ROE of +0.24%. Regarding short-term risk, SRTS is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs STE Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, STE has a market cap of 24.70B. Regarding current trading prices, SRTS is priced at $4.46, while STE trades at $251.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas STE's P/E ratio is 40.75. In terms of profitability, SRTS's ROE is +0.03%, compared to STE's ROE of +0.09%. Regarding short-term risk, SRTS is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs PODD Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, PODD has a market cap of 22.85B. Regarding current trading prices, SRTS is priced at $4.46, while PODD trades at $324.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas PODD's P/E ratio is 56.28. In terms of profitability, SRTS's ROE is +0.03%, compared to PODD's ROE of +0.35%. Regarding short-term risk, SRTS is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs PHG Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, PHG has a market cap of 22.24B. Regarding current trading prices, SRTS is priced at $4.46, while PHG trades at $24.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas PHG's P/E ratio is 82.90. In terms of profitability, SRTS's ROE is +0.03%, compared to PHG's ROE of +0.03%. Regarding short-term risk, SRTS is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs ZBH Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, ZBH has a market cap of 19.18B. Regarding current trading prices, SRTS is priced at $4.46, while ZBH trades at $96.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas ZBH's P/E ratio is 21.54. In terms of profitability, SRTS's ROE is +0.03%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, SRTS is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs ABMD Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, ABMD has a market cap of 17.18B. Regarding current trading prices, SRTS is priced at $4.46, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas ABMD's P/E ratio is 65.36. In terms of profitability, SRTS's ROE is +0.03%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, SRTS is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs ALGN Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, ALGN has a market cap of 13.65B. Regarding current trading prices, SRTS is priced at $4.46, while ALGN trades at $188.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas ALGN's P/E ratio is 34.17. In terms of profitability, SRTS's ROE is +0.03%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, SRTS is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs SNN Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, SNN has a market cap of 12.63B. Regarding current trading prices, SRTS is priced at $4.46, while SNN trades at $28.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas SNN's P/E ratio is 30.71. In terms of profitability, SRTS's ROE is +0.03%, compared to SNN's ROE of +0.08%. Regarding short-term risk, SRTS is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs SWAV Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, SWAV has a market cap of 12.57B. Regarding current trading prices, SRTS is priced at $4.46, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas SWAV's P/E ratio is 78.76. In terms of profitability, SRTS's ROE is +0.03%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, SRTS is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs PEN Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, PEN has a market cap of 10.87B. Regarding current trading prices, SRTS is priced at $4.46, while PEN trades at $280.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas PEN's P/E ratio is 262.29. In terms of profitability, SRTS's ROE is +0.03%, compared to PEN's ROE of +0.04%. Regarding short-term risk, SRTS is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs GMED Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, GMED has a market cap of 8.29B. Regarding current trading prices, SRTS is priced at $4.46, while GMED trades at $61.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas GMED's P/E ratio is 45.70. In terms of profitability, SRTS's ROE is +0.03%, compared to GMED's ROE of +0.05%. Regarding short-term risk, SRTS is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs BIO Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, BIO has a market cap of 6.78B. Regarding current trading prices, SRTS is priced at $4.46, while BIO trades at $248.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas BIO's P/E ratio is -3.80. In terms of profitability, SRTS's ROE is +0.03%, compared to BIO's ROE of -0.32%. Regarding short-term risk, SRTS is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs BIO-B Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, BIO-B has a market cap of 6.72B. Regarding current trading prices, SRTS is priced at $4.46, while BIO-B trades at $250.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas BIO-B's P/E ratio is -3.83. In terms of profitability, SRTS's ROE is +0.03%, compared to BIO-B's ROE of -0.32%. Regarding short-term risk, SRTS is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs BRKR Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, BRKR has a market cap of 5.69B. Regarding current trading prices, SRTS is priced at $4.46, while BRKR trades at $37.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas BRKR's P/E ratio is 72.17. In terms of profitability, SRTS's ROE is +0.03%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, SRTS is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs GKOS Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, GKOS has a market cap of 5.46B. Regarding current trading prices, SRTS is priced at $4.46, while GKOS trades at $95.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas GKOS's P/E ratio is -42.06. In terms of profitability, SRTS's ROE is +0.03%, compared to GKOS's ROE of -0.17%. Regarding short-term risk, SRTS is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs NARI Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, NARI has a market cap of 4.68B. Regarding current trading prices, SRTS is priced at $4.46, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas NARI's P/E ratio is -59.24. In terms of profitability, SRTS's ROE is +0.03%, compared to NARI's ROE of -0.18%. Regarding short-term risk, SRTS is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs INSP Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, INSP has a market cap of 4.51B. Regarding current trading prices, SRTS is priced at $4.46, while INSP trades at $152.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas INSP's P/E ratio is 72.40. In terms of profitability, SRTS's ROE is +0.03%, compared to INSP's ROE of +0.10%. Regarding short-term risk, SRTS is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs IRTC Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, IRTC has a market cap of 4.50B. Regarding current trading prices, SRTS is priced at $4.46, while IRTC trades at $141.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas IRTC's P/E ratio is -45.05. In terms of profitability, SRTS's ROE is +0.03%, compared to IRTC's ROE of -1.13%. Regarding short-term risk, SRTS is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs ITGR Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, ITGR has a market cap of 4.22B. Regarding current trading prices, SRTS is priced at $4.46, while ITGR trades at $120.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas ITGR's P/E ratio is 56.25. In terms of profitability, SRTS's ROE is +0.03%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, SRTS is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs TMDX Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, TMDX has a market cap of 4.11B. Regarding current trading prices, SRTS is priced at $4.46, while TMDX trades at $121.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas TMDX's P/E ratio is 85.02. In terms of profitability, SRTS's ROE is +0.03%, compared to TMDX's ROE of +0.22%. Regarding short-term risk, SRTS is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs AXNX Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, AXNX has a market cap of 3.63B. Regarding current trading prices, SRTS is priced at $4.46, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas AXNX's P/E ratio is -709.80. In terms of profitability, SRTS's ROE is +0.03%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, SRTS is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs PRCT Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, PRCT has a market cap of 3.21B. Regarding current trading prices, SRTS is priced at $4.46, while PRCT trades at $58.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas PRCT's P/E ratio is -34.36. In terms of profitability, SRTS's ROE is +0.03%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, SRTS is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs LIVN Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, LIVN has a market cap of 2.42B. Regarding current trading prices, SRTS is priced at $4.46, while LIVN trades at $44.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas LIVN's P/E ratio is -10.91. In terms of profitability, SRTS's ROE is +0.03%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, SRTS is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs NUVA Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, NUVA has a market cap of 2.08B. Regarding current trading prices, SRTS is priced at $4.46, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas NUVA's P/E ratio is 75.00. In terms of profitability, SRTS's ROE is +0.03%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, SRTS is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs UFPT Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, UFPT has a market cap of 1.95B. Regarding current trading prices, SRTS is priced at $4.46, while UFPT trades at $253.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas UFPT's P/E ratio is 31.12. In terms of profitability, SRTS's ROE is +0.03%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, SRTS is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs ATEC Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, ATEC has a market cap of 1.89B. Regarding current trading prices, SRTS is priced at $4.46, while ATEC trades at $12.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas ATEC's P/E ratio is -11.37. In terms of profitability, SRTS's ROE is +0.03%, compared to ATEC's ROE of -2.58%. Regarding short-term risk, SRTS is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs CNMD Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, CNMD has a market cap of 1.87B. Regarding current trading prices, SRTS is priced at $4.46, while CNMD trades at $60.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas CNMD's P/E ratio is 15.82. In terms of profitability, SRTS's ROE is +0.03%, compared to CNMD's ROE of +0.13%. Regarding short-term risk, SRTS is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs TNDM Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, TNDM has a market cap of 1.54B. Regarding current trading prices, SRTS is priced at $4.46, while TNDM trades at $23.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas TNDM's P/E ratio is -8.27. In terms of profitability, SRTS's ROE is +0.03%, compared to TNDM's ROE of -0.83%. Regarding short-term risk, SRTS is more volatile compared to TNDM. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs HSKA Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, HSKA has a market cap of 1.31B. Regarding current trading prices, SRTS is priced at $4.46, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas HSKA's P/E ratio is -62.49. In terms of profitability, SRTS's ROE is +0.03%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, SRTS is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs AORT Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, AORT has a market cap of 1.26B. Regarding current trading prices, SRTS is priced at $4.46, while AORT trades at $29.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas AORT's P/E ratio is -57.86. In terms of profitability, SRTS's ROE is +0.03%, compared to AORT's ROE of -0.07%. Regarding short-term risk, SRTS is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs AHCO Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, AHCO has a market cap of 1.22B. Regarding current trading prices, SRTS is priced at $4.46, while AHCO trades at $9.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas AHCO's P/E ratio is 15.55. In terms of profitability, SRTS's ROE is +0.03%, compared to AHCO's ROE of +0.06%. Regarding short-term risk, SRTS is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs SILK Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, SILK has a market cap of 1.12B. Regarding current trading prices, SRTS is priced at $4.46, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas SILK's P/E ratio is -18.96. In terms of profitability, SRTS's ROE is +0.03%, compared to SILK's ROE of -0.37%. Regarding short-term risk, SRTS is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs FNA Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, FNA has a market cap of 1.10B. Regarding current trading prices, SRTS is priced at $4.46, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas FNA's P/E ratio is -19.83. In terms of profitability, SRTS's ROE is +0.03%, compared to FNA's ROE of -0.36%. Regarding short-term risk, SRTS is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs IART Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, IART has a market cap of 1.05B. Regarding current trading prices, SRTS is priced at $4.46, while IART trades at $13.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas IART's P/E ratio is -35.71. In terms of profitability, SRTS's ROE is +0.03%, compared to IART's ROE of -0.03%. Regarding short-term risk, SRTS is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs ESTA Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, ESTA has a market cap of 1.05B. Regarding current trading prices, SRTS is priced at $4.46, while ESTA trades at $36.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas ESTA's P/E ratio is -12.05. In terms of profitability, SRTS's ROE is +0.03%, compared to ESTA's ROE of -2.10%. Regarding short-term risk, SRTS is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs INMD Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, INMD has a market cap of 1.02B. Regarding current trading prices, SRTS is priced at $4.46, while INMD trades at $14.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas INMD's P/E ratio is 6.52. In terms of profitability, SRTS's ROE is +0.03%, compared to INMD's ROE of +0.25%. Regarding short-term risk, SRTS is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs CSII Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, CSII has a market cap of 843.96M. Regarding current trading prices, SRTS is priced at $4.46, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas CSII's P/E ratio is -20.83. In terms of profitability, SRTS's ROE is +0.03%, compared to CSII's ROE of -0.14%. Regarding short-term risk, SRTS is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs CRY Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, CRY has a market cap of 725.15M. Regarding current trading prices, SRTS is priced at $4.46, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas CRY's P/E ratio is 425.71. In terms of profitability, SRTS's ROE is +0.03%, compared to CRY's ROE of -0.07%. Regarding short-term risk, SRTS is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs SIBN Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, SIBN has a market cap of 719.58M. Regarding current trading prices, SRTS is priced at $4.46, while SIBN trades at $16.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas SIBN's P/E ratio is -22.60. In terms of profitability, SRTS's ROE is +0.03%, compared to SIBN's ROE of -0.16%. Regarding short-term risk, SRTS is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs IRMD Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, IRMD has a market cap of 685.47M. Regarding current trading prices, SRTS is priced at $4.46, while IRMD trades at $53.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas IRMD's P/E ratio is 34.78. In terms of profitability, SRTS's ROE is +0.03%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, SRTS is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs CBLL Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, CBLL has a market cap of 649.49M. Regarding current trading prices, SRTS is priced at $4.46, while CBLL trades at $17.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas CBLL's P/E ratio is -14.38. In terms of profitability, SRTS's ROE is +0.03%, compared to CBLL's ROE of -1.64%. Regarding short-term risk, SRTS is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs AVNS Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, AVNS has a market cap of 606.72M. Regarding current trading prices, SRTS is priced at $4.46, while AVNS trades at $13.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas AVNS's P/E ratio is -1.56. In terms of profitability, SRTS's ROE is +0.03%, compared to AVNS's ROE of -0.37%. Regarding short-term risk, SRTS is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs BFLY Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, BFLY has a market cap of 583.20M. Regarding current trading prices, SRTS is priced at $4.46, while BFLY trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas BFLY's P/E ratio is -7.87. In terms of profitability, SRTS's ROE is +0.03%, compared to BFLY's ROE of -0.33%. Regarding short-term risk, SRTS is more volatile compared to BFLY. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs APEN Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, APEN has a market cap of 579.72M. Regarding current trading prices, SRTS is priced at $4.46, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas APEN's P/E ratio is -9.43. In terms of profitability, SRTS's ROE is +0.03%, compared to APEN's ROE of -0.85%. Regarding short-term risk, SRTS is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs RXST Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, RXST has a market cap of 576.64M. Regarding current trading prices, SRTS is priced at $4.46, while RXST trades at $14.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas RXST's P/E ratio is -21.50. In terms of profitability, SRTS's ROE is +0.03%, compared to RXST's ROE of -0.10%. Regarding short-term risk, SRTS is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for SRTS.
SRTS vs BFLY-WT Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, BFLY-WT has a market cap of 575.60M. Regarding current trading prices, SRTS is priced at $4.46, while BFLY-WT trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, SRTS's ROE is +0.03%, compared to BFLY-WT's ROE of -0.33%. Regarding short-term risk, SRTS is more volatile compared to BFLY-WT. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs NPCE Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, NPCE has a market cap of 573.65M. Regarding current trading prices, SRTS is priced at $4.46, while NPCE trades at $17.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas NPCE's P/E ratio is -18.81. In terms of profitability, SRTS's ROE is +0.03%, compared to NPCE's ROE of -1.40%. Regarding short-term risk, SRTS is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for SRTS.
SRTS vs KIDS Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, KIDS has a market cap of 571.42M. Regarding current trading prices, SRTS is priced at $4.46, while KIDS trades at $23.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas KIDS's P/E ratio is -13.11. In terms of profitability, SRTS's ROE is +0.03%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, SRTS is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs AXGN Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, AXGN has a market cap of 538.79M. Regarding current trading prices, SRTS is priced at $4.46, while AXGN trades at $11.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas AXGN's P/E ratio is -51.43. In terms of profitability, SRTS's ROE is +0.03%, compared to AXGN's ROE of -0.07%. Regarding short-term risk, SRTS is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs OFIX Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, OFIX has a market cap of 475.65M. Regarding current trading prices, SRTS is priced at $4.46, while OFIX trades at $12.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas OFIX's P/E ratio is -3.28. In terms of profitability, SRTS's ROE is +0.03%, compared to OFIX's ROE of -0.28%. Regarding short-term risk, SRTS is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs BVS Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, BVS has a market cap of 450.57M. Regarding current trading prices, SRTS is priced at $4.46, while BVS trades at $6.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas BVS's P/E ratio is -14.15. In terms of profitability, SRTS's ROE is +0.03%, compared to BVS's ROE of -0.21%. Regarding short-term risk, SRTS is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs TMCI Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, TMCI has a market cap of 422.72M. Regarding current trading prices, SRTS is priced at $4.46, while TMCI trades at $6.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas TMCI's P/E ratio is -7.91. In terms of profitability, SRTS's ROE is +0.03%, compared to TMCI's ROE of -0.49%. Regarding short-term risk, SRTS is more volatile compared to TMCI. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs SRDX Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, SRDX has a market cap of 408.67M. Regarding current trading prices, SRTS is priced at $4.46, while SRDX trades at $28.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas SRDX's P/E ratio is -28.02. In terms of profitability, SRTS's ROE is +0.03%, compared to SRDX's ROE of -0.17%. Regarding short-term risk, SRTS is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs CLPT Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, CLPT has a market cap of 372.53M. Regarding current trading prices, SRTS is priced at $4.46, while CLPT trades at $13.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas CLPT's P/E ratio is -18.05. In terms of profitability, SRTS's ROE is +0.03%, compared to CLPT's ROE of -0.78%. Regarding short-term risk, SRTS is more volatile compared to CLPT. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs NNOX Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, NNOX has a market cap of 357.07M. Regarding current trading prices, SRTS is priced at $4.46, while NNOX trades at $5.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas NNOX's P/E ratio is -6.15. In terms of profitability, SRTS's ROE is +0.03%, compared to NNOX's ROE of -0.30%. Regarding short-term risk, SRTS is more volatile compared to NNOX. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs OM Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, OM has a market cap of 345.59M. Regarding current trading prices, SRTS is priced at $4.46, while OM trades at $19.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas OM's P/E ratio is -0.68. In terms of profitability, SRTS's ROE is +0.03%, compared to OM's ROE of -1.45%. Regarding short-term risk, SRTS is less volatile compared to OM. This indicates potentially lower risk in terms of short-term price fluctuations for SRTS.
SRTS vs SENS Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, SENS has a market cap of 338.99M. Regarding current trading prices, SRTS is priced at $4.46, while SENS trades at $0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas SENS's P/E ratio is -4.71. In terms of profitability, SRTS's ROE is +0.03%, compared to SENS's ROE of -7.46%. Regarding short-term risk, SRTS is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for SRTS.
SRTS vs CTKB Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, CTKB has a market cap of 338.18M. Regarding current trading prices, SRTS is priced at $4.46, while CTKB trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas CTKB's P/E ratio is -29.67. In terms of profitability, SRTS's ROE is +0.03%, compared to CTKB's ROE of -0.03%. Regarding short-term risk, SRTS is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs VREX Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, VREX has a market cap of 327.02M. Regarding current trading prices, SRTS is priced at $4.46, while VREX trades at $7.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas VREX's P/E ratio is -7.65. In terms of profitability, SRTS's ROE is +0.03%, compared to VREX's ROE of -0.08%. Regarding short-term risk, SRTS is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs SMLR Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, SMLR has a market cap of 312.27M. Regarding current trading prices, SRTS is priced at $4.46, while SMLR trades at $32.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas SMLR's P/E ratio is 6.34. In terms of profitability, SRTS's ROE is +0.03%, compared to SMLR's ROE of -0.21%. Regarding short-term risk, SRTS is less volatile compared to SMLR. This indicates potentially lower risk in terms of short-term price fluctuations for SRTS.
SRTS vs PACB Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, PACB has a market cap of 310.59M. Regarding current trading prices, SRTS is priced at $4.46, while PACB trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas PACB's P/E ratio is -0.38. In terms of profitability, SRTS's ROE is +0.03%, compared to PACB's ROE of -1.25%. Regarding short-term risk, SRTS is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for SRTS.
SRTS vs VMD Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, VMD has a market cap of 267.18M. Regarding current trading prices, SRTS is priced at $4.46, while VMD trades at $6.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas VMD's P/E ratio is 22.53. In terms of profitability, SRTS's ROE is +0.03%, compared to VMD's ROE of +0.10%. Regarding short-term risk, SRTS is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs CERS Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, CERS has a market cap of 254.24M. Regarding current trading prices, SRTS is priced at $4.46, while CERS trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas CERS's P/E ratio is -13.30. In terms of profitability, SRTS's ROE is +0.03%, compared to CERS's ROE of -0.35%. Regarding short-term risk, SRTS is more volatile compared to CERS. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs ZIMV Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, ZIMV has a market cap of 251.57M. Regarding current trading prices, SRTS is priced at $4.46, while ZIMV trades at $9.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas ZIMV's P/E ratio is -7.33. In terms of profitability, SRTS's ROE is +0.03%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, SRTS is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs MXCT Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, MXCT has a market cap of 244.53M. Regarding current trading prices, SRTS is priced at $4.46, while MXCT trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas MXCT's P/E ratio is -5.75. In terms of profitability, SRTS's ROE is +0.03%, compared to MXCT's ROE of -0.20%. Regarding short-term risk, SRTS is more volatile compared to MXCT. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs TCMD Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, TCMD has a market cap of 241.78M. Regarding current trading prices, SRTS is priced at $4.46, while TCMD trades at $10.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas TCMD's P/E ratio is 15.76. In terms of profitability, SRTS's ROE is +0.03%, compared to TCMD's ROE of +0.08%. Regarding short-term risk, SRTS is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for SRTS.
SRTS vs NVRO Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, NVRO has a market cap of 224.09M. Regarding current trading prices, SRTS is priced at $4.46, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas NVRO's P/E ratio is -1.91. In terms of profitability, SRTS's ROE is +0.03%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, SRTS is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs EYES Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, EYES has a market cap of 210.05M. Regarding current trading prices, SRTS is priced at $4.46, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas EYES's P/E ratio is N/A. In terms of profitability, SRTS's ROE is +0.03%, compared to EYES's ROE of -0.26%. Regarding short-term risk, SRTS is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs CATX Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, CATX has a market cap of 197.82M. Regarding current trading prices, SRTS is priced at $4.46, while CATX trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas CATX's P/E ratio is -1.95. In terms of profitability, SRTS's ROE is +0.03%, compared to CATX's ROE of -0.27%. Regarding short-term risk, SRTS is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for SRTS.
SRTS vs BWAY Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, BWAY has a market cap of 190.61M. Regarding current trading prices, SRTS is priced at $4.46, while BWAY trades at $10.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas BWAY's P/E ratio is 56.11. In terms of profitability, SRTS's ROE is +0.03%, compared to BWAY's ROE of +0.06%. Regarding short-term risk, SRTS is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs QTRX Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, QTRX has a market cap of 185.99M. Regarding current trading prices, SRTS is priced at $4.46, while QTRX trades at $4.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas QTRX's P/E ratio is -3.86. In terms of profitability, SRTS's ROE is +0.03%, compared to QTRX's ROE of -0.15%. Regarding short-term risk, SRTS is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for SRTS.
SRTS vs SGHT Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, SGHT has a market cap of 183.54M. Regarding current trading prices, SRTS is priced at $4.46, while SGHT trades at $3.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas SGHT's P/E ratio is -3.62. In terms of profitability, SRTS's ROE is +0.03%, compared to SGHT's ROE of -0.55%. Regarding short-term risk, SRTS is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs ELMD Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, ELMD has a market cap of 180.68M. Regarding current trading prices, SRTS is priced at $4.46, while ELMD trades at $21.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas ELMD's P/E ratio is 28.73. In terms of profitability, SRTS's ROE is +0.03%, compared to ELMD's ROE of +0.17%. Regarding short-term risk, SRTS is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for SRTS.
SRTS vs BDMD Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, BDMD has a market cap of 180.44M. Regarding current trading prices, SRTS is priced at $4.46, while BDMD trades at $5.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas BDMD's P/E ratio is 14.54. In terms of profitability, SRTS's ROE is +0.03%, compared to BDMD's ROE of +0.12%. Regarding short-term risk, SRTS is more volatile compared to BDMD. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs ANIK Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, ANIK has a market cap of 174.82M. Regarding current trading prices, SRTS is priced at $4.46, while ANIK trades at $12.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas ANIK's P/E ratio is -16.25. In terms of profitability, SRTS's ROE is +0.03%, compared to ANIK's ROE of -0.33%. Regarding short-term risk, SRTS is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs RCEL Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, RCEL has a market cap of 170.77M. Regarding current trading prices, SRTS is priced at $4.46, while RCEL trades at $6.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas RCEL's P/E ratio is -2.70. In terms of profitability, SRTS's ROE is +0.03%, compared to RCEL's ROE of -3.38%. Regarding short-term risk, SRTS is more volatile compared to RCEL. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs LNSR Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, LNSR has a market cap of 166.39M. Regarding current trading prices, SRTS is priced at $4.46, while LNSR trades at $14.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas LNSR's P/E ratio is -5.17. In terms of profitability, SRTS's ROE is +0.03%, compared to LNSR's ROE of -5.28%. Regarding short-term risk, SRTS is more volatile compared to LNSR. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs TLSI Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, TLSI has a market cap of 166.20M. Regarding current trading prices, SRTS is priced at $4.46, while TLSI trades at $5.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas TLSI's P/E ratio is -3.92. In terms of profitability, SRTS's ROE is +0.03%, compared to TLSI's ROE of +1.07%. Regarding short-term risk, SRTS is more volatile compared to TLSI. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs CVRX Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, CVRX has a market cap of 165.30M. Regarding current trading prices, SRTS is priced at $4.46, while CVRX trades at $6.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas CVRX's P/E ratio is -2.96. In terms of profitability, SRTS's ROE is +0.03%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, SRTS is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for SRTS.
SRTS vs MASS Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, MASS has a market cap of 164.24M. Regarding current trading prices, SRTS is priced at $4.46, while MASS trades at $4.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas MASS's P/E ratio is -2.16. In terms of profitability, SRTS's ROE is +0.03%, compared to MASS's ROE of -0.13%. Regarding short-term risk, SRTS is more volatile compared to MASS. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs INGN Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, INGN has a market cap of 163.74M. Regarding current trading prices, SRTS is priced at $4.46, while INGN trades at $6.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas INGN's P/E ratio is -5.30. In terms of profitability, SRTS's ROE is +0.03%, compared to INGN's ROE of -0.15%. Regarding short-term risk, SRTS is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs AVR Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, AVR has a market cap of 149.15M. Regarding current trading prices, SRTS is priced at $4.46, while AVR trades at $4.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas AVR's P/E ratio is -2.10. In terms of profitability, SRTS's ROE is +0.03%, compared to AVR's ROE of -2.92%. Regarding short-term risk, SRTS is more volatile compared to AVR. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs PROF Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, PROF has a market cap of 141.55M. Regarding current trading prices, SRTS is priced at $4.46, while PROF trades at $4.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas PROF's P/E ratio is -3.89. In terms of profitability, SRTS's ROE is +0.03%, compared to PROF's ROE of -0.70%. Regarding short-term risk, SRTS is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs RPID Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, RPID has a market cap of 140.70M. Regarding current trading prices, SRTS is priced at $4.46, while RPID trades at $3.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas RPID's P/E ratio is -3.12. In terms of profitability, SRTS's ROE is +0.03%, compared to RPID's ROE of -0.56%. Regarding short-term risk, SRTS is more volatile compared to RPID. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs LUNG Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, LUNG has a market cap of 138.08M. Regarding current trading prices, SRTS is priced at $4.46, while LUNG trades at $3.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas LUNG's P/E ratio is -2.38. In terms of profitability, SRTS's ROE is +0.03%, compared to LUNG's ROE of -0.64%. Regarding short-term risk, SRTS is more volatile compared to LUNG. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs LUCD Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, LUCD has a market cap of 136.32M. Regarding current trading prices, SRTS is priced at $4.46, while LUCD trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas LUCD's P/E ratio is -1.20. In terms of profitability, SRTS's ROE is +0.03%, compared to LUCD's ROE of +26.96%. Regarding short-term risk, SRTS is more volatile compared to LUCD. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs MYO Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, MYO has a market cap of 128.08M. Regarding current trading prices, SRTS is priced at $4.46, while MYO trades at $3.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas MYO's P/E ratio is -25.43. In terms of profitability, SRTS's ROE is +0.03%, compared to MYO's ROE of -0.36%. Regarding short-term risk, SRTS is less volatile compared to MYO. This indicates potentially lower risk in terms of short-term price fluctuations for SRTS.
SRTS vs ICAD Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, ICAD has a market cap of 109.51M. Regarding current trading prices, SRTS is priced at $4.46, while ICAD trades at $3.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas ICAD's P/E ratio is -19.00. In terms of profitability, SRTS's ROE is +0.03%, compared to ICAD's ROE of -0.17%. Regarding short-term risk, SRTS is more volatile compared to ICAD. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs HJLI Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, HJLI has a market cap of 98.32M. Regarding current trading prices, SRTS is priced at $4.46, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas HJLI's P/E ratio is N/A. In terms of profitability, SRTS's ROE is +0.03%, compared to HJLI's ROE of -0.51%. Regarding short-term risk, SRTS is more volatile compared to HJLI. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs XTNT Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, XTNT has a market cap of 95.76M. Regarding current trading prices, SRTS is priced at $4.46, while XTNT trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas XTNT's P/E ratio is -5.73. In terms of profitability, SRTS's ROE is +0.03%, compared to XTNT's ROE of -0.27%. Regarding short-term risk, SRTS is less volatile compared to XTNT. This indicates potentially lower risk in terms of short-term price fluctuations for SRTS.
SRTS vs ASXC Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, ASXC has a market cap of 94.92M. Regarding current trading prices, SRTS is priced at $4.46, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas ASXC's P/E ratio is -1.12. In terms of profitability, SRTS's ROE is +0.03%, compared to ASXC's ROE of -4.07%. Regarding short-term risk, SRTS is more volatile compared to ASXC. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs MGRM Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, MGRM has a market cap of 92.43M. Regarding current trading prices, SRTS is priced at $4.46, while MGRM trades at $2.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas MGRM's P/E ratio is -5.08. In terms of profitability, SRTS's ROE is +0.03%, compared to MGRM's ROE of -1.26%. Regarding short-term risk, SRTS is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.
SRTS vs OWLT Comparison
SRTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRTS stands at 73.57M. In comparison, OWLT has a market cap of 87.50M. Regarding current trading prices, SRTS is priced at $4.46, while OWLT trades at $5.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRTS currently has a P/E ratio of 10.88, whereas OWLT's P/E ratio is -3.29. In terms of profitability, SRTS's ROE is +0.03%, compared to OWLT's ROE of +1.37%. Regarding short-term risk, SRTS is more volatile compared to OWLT. This indicates potentially higher risk in terms of short-term price fluctuations for SRTS.